Peculiarities of Clinical Symptoms, Somatic Complications, Approaches to Therapy and Outcomes of Delirium Induced by Exposure to Synthetic Cannabinoids: Systematic Review

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

INTRODUCTION: The use of synthetic cannabinoids (SCs) is an urgent healthcare problem, due to, among other things, a high number of complications.

AIM: To systematize the peculiarities of clinical presentation, somatic complications, effectiveness of empirical approaches to therapy, and probable outcomes of delirium induced by exposure to SCs.

MATERIALS AND METHODS: The analysis of scientific publications selected by the keywords in eLibrary, СNKI, PubMed databases, was conducted. According to PRISMA recommendations, 20 articles were taken for analysis.

RESULTS: Today, it is impossible to predict the period when SC-induced delirium may occur. It can start after one-time intake of even small dose, and can occur both due to intoxication and with the underlying withdrawal state — on the 2nd–4th days after the last use. Besides classic symptoms, the clinical picture of delirium is characterized by many symptoms of schizophrenic psychoses: hallucinations of threatening or drug-addicted content; secondary paranoid delusion, less expressed than hallucinations; aggressiveness and agitated behavior; some formal thinking disorders; rarely, Kandinski–Clerambault and oneiroid syndromes. There are reported cases of severe somatic complications in the form of depression of consciousness, rhabdomyolysis, acute renal failure, cardiomyopathy, myocardial infarction, epilepsy, infectious complications with the underlying weakened immunity. Therapy of SC-induced delirium includes detoxification and metabolic therapy, administration of antipsychotics and tranquilizers; use of resuscitation measures in case of depression of consciousness and development of life-threatening conditions. SC-induced delirium lasts from several hours to several days. In most cases, it terminates with complete recovery with amnesia of the period of confusion and asthenia, but in some cases fatal outcomes are reported caused not only by accidents such as road accidents or suicide, but also by somatic complications (most often of infectious character, or multi-organ failure).

CONCLUSION: SСs remain relevant due to high frequency of their use and continuous emergence of new analogs to substances of this group. They have multidirectional effect, and so far it is difficult to predict at what period the delirium induced by them may occur.

Full Text

Restricted Access

About the authors

Ilya A. Fedotov

Ryazan State Medical University

Email: ilyafdtv@yandex.ru
ORCID iD: 0000-0002-2791-7180
SPIN-code: 4004-4132

MD, Cand. Sci. (Med), Associate Professor

Russian Federation, Ryazan

Boris Yu. Volodin

Ryazan State Medical University

Email: borisvolodin@rambler.ru
ORCID iD: 0000-0001-7355-4483
SPIN-code: 8374-0562

MD, Dr. Sci. (Med.), Professor

Russian Federation, Ryazan

Vladimir V. Novikov

Ryazan State Medical University

Email: novlad2006@yandex.ru
ORCID iD: 0000-0003-3132-4959
SPIN-code: 9322-7985

MD, Dr. Sci. (Med.), Associate Professor

Russian Federation, Ryazan

Dmitriy I. Shustov

Ryazan State Medical University

Author for correspondence.
Email: dmitri_shustov@mail.ru
ORCID iD: 0000-0001-7803-3388
SPIN-code: 3887-5475

MD, Dr. Sci. (Med.), Professor

Russian Federation, Ryazan

References

  1. UNODS. World drug report 2022. Vienna: Vienna intern. centre; 2022. Available at: https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report-2022.html. Accessed: 21.02.2023.
  2. Asadullin AR, Akhmetova EA, Yefremov IS, et al. New psychoactive substances (designer drugs): an approach to classification. Psychiatry and Psychopharmacotherapy. 2019;21(5):4–9. (In Russ).
  3. Klimenko TV, Shakhova SM, Kozlov AA. Psychotic disorders after use of synthetic cannabinoids (spice). Siberian Herald of Psychiatry and Addiction Psychiatry. 2017;(2):26–30. (In Russ).
  4. Alves VL, Gonçalves JL, Aguiar J, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359–82. doi: 10.1080/10408444.2020.1762539
  5. Armstrong F, McCurdy MT, Heavner MS. Synthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review. Pharmacotherapy. 2019;39(4):508–13. doi: 10.1002/phar.2241
  6. Hobbs M, Kalk NJ, Morrison PD, et al. M. Spicing it up — synthetic cannabinoid receptor agonists and psychosis — a systematic review. Eur Neuropsychopharmacol. 2018;28(12):1289–304. doi: 10.1016/j.euroneuro.2018.10.004
  7. ICD-11. Chapter 06. Mental and behavioral disorders and disorders of neuropsychic development. Statistical classification. Moscow; 2021. (In Russ). doi: 10.31453/kdu.ru.91304.0143
  8. Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and refinement: updated guidance and examples for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160
  9. Bokhan NA, Selivanov GYu. Clinical typology of psychopathological disorders in users of synthetic cannabinoids (spice). Siberian Herald of Psychiatry and Addiction Psychiatry. 2015;(4):18–23. (In Russ).
  10. Berdnikova EA, Bayalieva AZh, Ustimov DYu, et al. Pathogenetically based sedative therapy of heavy delirium in overdose of synthetic cannabinoids. Vrach Skoroy Pomoshchi. 2017;(4):59–67. (In Russ).
  11. Davydova VR, Ustimov DYu, Berdnikova EA. Patogeneticheski obosnovannaya efferentnaya i infuzionnaya terapiya tyazhelogo deliriya pri peredozirovke sinteticheskikh kannabinoidov. In: Aktual’nyye voprosy i innovatsionnyye tekhnologii v anesteziologii i reanimatologii: materialy nauchno-obrazovatel’noy konferentsii, Saint-Petersburg, 30–31 March 2018. Saint-Petersburg; 2018. P. 9–18. (In Russ).
  12. Rakitin SA, Usov GM. Typology of psychotic disorders, associated with modern synthetic psychoactive substances. Psychiatry and Psychopharmacotherapy. 2020;22(6):31–6. (In Russ).
  13. Ivanova LA, Terskikh TV, Tarasenko TV, et al. Psychotic disorders in people using synthetic cannabinoids (spices). Acta Biomedica Scientifica. 2017;2(2):14–7. (In Russ). doi: 10.12737/article_59a614f6883957.55938557
  14. Rakitin SA, Kukushkin MV, Mishchenko SV, et al. A clinical example of psychosis developed against the background of acute intoxication with synthetic cannabinoids. Omsk Journal of Psychiatry. 2020;(2):8–11. (In Russ). doi: 10.24411/2412-8805-2020-10206
  15. Vinnikova MA, Skryabin VYu. Psikhopatologicheskiye varianty psikhozov pri upotreblenii sinteticheskikh kannabinoidov. In: Interdistsiplinarnyy podkhod k komorbidnosti psikhicheskikh rasstroystv na puti k integrativnomu lecheniyu: sbornik tezisov, Saint-Petersburg, 15–18 May 2021. Saint-Petersburg: V. M. Bekhterev National Medical Research Center of Psychiatry and Neurology; 2021. P. 1099–100. (In Russ).
  16. Vdovin AS. Clinical variants of psychoses associated with the use of synthetic cannabinoids. Narcology. 2022;(8):49–55. (In Russ). doi: 10.25557/1682-8313.2022.08.49-55
  17. Patrikeeva ON, Ovchinnikov AA, Kormilina OM. Intoxication psychosis consumers synthetic cannabinoids. Narcology. 2015;(1):41–4. (In Russ).
  18. Kekelidze ZI, Klimenko TV, Kozlov AA, et al. Therapy of acute psychosis due to use of synthetic cannabinoids. Siberian Herald of Psychiatry and Addiction Psychiatry. 2017;(3):16–20. (In Russ). doi: 10.26617/1810-3111-2017-3(96)-16-20
  19. Gareeva AE, Sharafiev RR, Akhmetova EA, et al. The combined effect of genetic factors and attention deficit hyperactivity disorder on the development of dependence on synthetic cannabinoids. Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 2020;120(2):15–21. (In Russ). doi: 10.17116/jnevro202012002115
  20. Tyndall JA, Gerona R, de Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol. 2015;53(10):950–6. doi: 10.3109/15563650.2015.1100306
  21. Armenian P, Darracq M, Gevorkyan J, et al. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature. Neuropharmacology. 2018;134(Pt A):82–91. doi: 10.1016/j.neuropharm.2017.10.017
  22. Yazici AB, Yazici E, Erol A. Delirium and High Creatine Kinase and Myoglobin Levels Related to Synthetic Cannabinoid Withdrawal. Case Rep Med. 2017;2017:3894749. doi: 10.1155/2017/3894749
  23. Sweeney B, Talebi S, Toro D, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34(1): 121.e1–2. doi: 10.1016/j.ajem.2015.05.052
  24. Labay LM, Caruso JL, Gilson TP, et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int. 2016;260:31–9. doi: 10.1016/j.forsciint.2015.12.046
  25. Dmitrieva TB, Igonin AL, Klimenko TV, et al. Acute intoxication of psychoactive substances including opioides, cannabinoides, sedative and stimulative drugs, hallucinogens and solvents. Narcology. 2002;(7):8–12. (In Russ).
  26. Ergül DF, Ekemen S, Yelken BB. Synthetic Cannabinoid ‘Bonzai’ Intoxication: Six Case Series. Turk J Anaesthesiol Reanim. 2015;43(5): 347–51. doi: 10.5152/TJAR.2015.05668
  27. Schwartz MD, Trecki J, Edison LA, et al. A common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA. J Emerg Med. 2015;48(5):573–80. doi: 10.1016/j.jemermed.2014.12.038
  28. Brandehoff N, Adams A, McDaniel K, et al. Synthetic cannabinoid “Black Mamba” infidelity in patients presenting for emergency stabilization in Colorado: a P-SCAN Cohort. Clin Toxicol (Phila). 2018;56(3):193–8. doi: 10.1080/15563650.2017.1357826
  29. Sinevich AA, Kopytov AV. Analiz produktivnoy simptomatiki po shkale pozitivnykh simptomov PANSS, u lits muzhskogo pola s zavisimost’yu ot kuritel’nykh smesey iz Respubliki Belarus’. Voyennaya Meditsina. 2016;(3):64–70. (In Russ).
  30. Mendelevich VD. Psychotic disorders due to drug use: current state of the problem. Narcology. 2014;13(7):93–100. (In Russ).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Schematic presentation of selection of literature sources according to PRISMA recommendations [8].

Download (60KB)
Indexing metadata
3. Рис. 1. Схематическое изображение отбора литературных источников в соответствии с рекомендациями PRISMA [8].

Download (79KB)
Indexing metadata

Copyright (c) 2023 Eco-Vector


Media Registry Entry of the Federal Service for Supervision of Communications, Information Technology and Mass Communications (Roskomnadzor) PI No. FS77-76803 dated September 24, 2019.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies